Astellas Pharma Inc
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to m… Read more
Astellas Pharma Inc (ALPMF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.043x
Based on the latest financial reports, Astellas Pharma Inc (ALPMF) has a cash flow conversion efficiency ratio of 0.043x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($75.84 Billion) by net assets ($1.77 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Astellas Pharma Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Astellas Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Astellas Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Astellas Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
B3 S.A. - Brasil Bolsa Balcão
PINK:BOLSY
|
0.081x |
|
Tbea Co Ltd
SHG:600089
|
0.017x |
|
Global Payments Inc
NYSE:GPN
|
0.033x |
|
Yum China Holdings Inc
NYSE:YUMC
|
0.076x |
|
PTT Exploration & Production
PINK:PEXNY
|
0.080x |
|
FOX CORP. A DL-01
F:FO5
|
N/A |
|
Fresenius SE & Co. KGaA
PINK:FSNUF
|
0.039x |
|
LENNAR CORP. B DL-10
F:LNN0
|
N/A |
Annual Cash Flow Conversion Efficiency for Astellas Pharma Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Astellas Pharma Inc from 2004 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $1.51 Trillion | $194.51 Billion | 0.129x | +18.94% |
| 2024-03-31 | $1.60 Trillion | $172.47 Billion | 0.108x | -50.28% |
| 2023-03-31 | $1.51 Trillion | $327.77 Billion | 0.217x | +23.29% |
| 2022-03-31 | $1.46 Trillion | $257.44 Billion | 0.176x | -20.36% |
| 2021-03-31 | $1.39 Trillion | $306.84 Billion | 0.221x | +28.55% |
| 2020-03-31 | $1.29 Trillion | $222.00 Billion | 0.172x | -16.21% |
| 2019-03-31 | $1.26 Trillion | $258.63 Billion | 0.206x | -16.62% |
| 2018-03-31 | $1.27 Trillion | $312.61 Billion | 0.246x | +33.05% |
| 2017-03-31 | $1.27 Trillion | $235.61 Billion | 0.185x | -25.65% |
| 2016-03-31 | $1.26 Trillion | $313.74 Billion | 0.249x | +74.95% |
| 2015-03-31 | $1.32 Trillion | $187.69 Billion | 0.142x | -15.69% |
| 2014-03-31 | $1.27 Trillion | $214.26 Billion | 0.169x | +24.44% |
| 2013-03-31 | $1.06 Trillion | $144.15 Billion | 0.136x | -19.97% |
| 2012-03-31 | $1.02 Trillion | $172.68 Billion | 0.170x | +72.08% |
| 2011-03-31 | $1.02 Trillion | $100.64 Billion | 0.099x | -30.81% |
| 2010-03-31 | $1.05 Trillion | $150.13 Billion | 0.142x | -25.80% |
| 2009-03-31 | $1.03 Trillion | $197.79 Billion | 0.192x | +14.09% |
| 2008-03-31 | $1.11 Trillion | $186.93 Billion | 0.168x | +44.56% |
| 2007-03-31 | $1.10 Trillion | $127.93 Billion | 0.116x | +1.11% |
| 2006-03-31 | $1.22 Trillion | $140.15 Billion | 0.115x | +76.17% |
| 2005-03-31 | $743.47 Billion | $48.59 Billion | 0.065x | +9.66% |
| 2004-03-31 | $727.86 Billion | $43.38 Billion | 0.060x | -- |